Icagen to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Jul 9, 2007 -Icagen, Inc. (NASDAQ: ICGN) today announced that P. Kay Wagoner,Ph.D., Chief Executive Officer, will present at the C.E. Unterberg,Towbin Emerging Growth Opportunities Conference in New York City onThursday, July 12th at 2:00 p.m. ET. There will be a live webcast of this presentation from theconference. The webcast will be access...Icagen Terminates Phase III ASSERT Study
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Apr 3, 2007 -Icagen, Inc. (NASDAQ: ICGN) announced today that following aplanned meeting of the independent Data Monitoring Committee("DMC") of the Company's ASSERT trial of senicapoc (formerlyICA-17043) for the treatment of sickle cell disease in adults, theDMC recommended that the trial be terminated because of the lowprobability of achieving...